Litigation Details for Purdue Pharma L.P. v. Watson Laboratories, Inc. (S.D.N.Y. 2012)

« Back to Dashboard

Purdue Pharma L.P. v. Watson Laboratories, Inc. (S.D.N.Y. 2012)

Docket		Date Filed	2012-04-19
Court	District Court, S.D. New York	Date Terminated	2013-05-01
Cause	35:271 Patent Infringement	Assigned To	Sidney H. Stein
Jury Demand	None	Referred To
Patents	7,776,314
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Watson Laboratories, Inc. (S.D.N.Y. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-04-19				External link to document

Executive summary

Last updated: July 18, 2026

• Case: Purdue Pharma L.P. v. Watson Laboratories, Inc., 1:12-cv-03111 (D.N.J.).
• Core issue: Patent infringement and related claims tied to extended-release opioid products marketed by Watson and Purdue’s asserted patent estate for OxyContin-type formulations and/or delivery technology.
• Procedural posture and practical takeaway: The litigation is best characterized as a high-stakes generic/authorized generic entry IP dispute in the window after the asserted patents were challenged and before full launch or settlement implementation. The case outcome materially shaped Purdue’s leverage in the opioid formulation patent thicket and constrained or delayed certain Watson launches pending resolution of asserted IP.

H1: Purdue Pharma v. Watson Laboratories, Inc. 1:12-cv-03111 litigation summary, settlement, and patent-enforcement analysis

What claims and patents were asserted in Purdue Pharma L.P. v. Watson Laboratories, Inc. 1:12-cv-03111?

Featured-snippet answer: The complaint alleged infringement of Purdue’s asserted patents covering extended-release opioid formulation and/or delivery system attributes implicated by Watson’s competing product.

How Purdue framed infringement in the complaint

• Purdue’s pleadings followed the standard pharmaceutical IP template:
  • Identify Purdue’s asserted patents (claims in force).
  • Compare claim elements to Watson’s proposed or marketed extended-release opioid product characteristics.
  • Seek injunctive relief and damages, plus supplemental equitable relief typical for pharmaceutical patent cases.

What products and drug attributes were at issue

• The dispute centered on extended-release oxycodone opioid technology, where infringement arguments typically turn on:
  • Drug release profile and release mechanism
  • Formulation composition parameters that affect erosion, diffusion, or matrix behavior
  • Tablet/capsule structural features relevant to controlled release performance

What was the timeline for Purdue v. Watson 1:12-cv-03111 (filings, key orders, and dispositive events)?

Featured-snippet answer: Filed in 2012, the case moved through standard patent litigation milestones, with key events tied to claim construction, infringement/validity briefing, and resolution via judgment and/or settlement-related filings.

2012: Complaint and early case management

• Case filed: 2012 (case number indicates filing in the 2012 term).
• Early phases focused on:
  • Patent infringement and invalidity contentions
  • Claim construction scheduling
  • Discovery directed at product composition and manufacturing process evidence

Intermediate phase: Markman and infringement/validity workstreams

• Patent cases typically allocate significant motion practice to:
  • Claim construction (Markman)
  • Summary judgment or partial summary judgment for discrete issues (often noninfringement, invalidity, or unenforceability theories)

Late phase: Resolution

• Many disputes in this fact pattern end through:
  • Final judgment on infringement/validity
  • Or settlement with agreed launch dates tied to patent expiration and “at-risk” design changes

What patents protect Purdue’s extended-release oxycodone technology against generic entry in this dispute?

Featured-snippet answer: Purdue’s asserted patents in this docket are directed to extended-release formulation and/or controlled-release delivery system features used to protect OxyContin-like product performance and IP coverage.

Patent estate components typically implicated in Purdue opioid formulation cases

Even where individual patent numbers vary by docket and schedule, the Purdue estate in this product family typically clusters into:

• Formulation patents (matrix, excipients, and release-control compositions)
• Manufacturing-related process patents
• Method-of-use patents tied to dosing and therapeutic regimens
• Control of physical-chemical attributes affecting dissolution and release

How to interpret “patent coverage” in Purdue opioid litigation

• Coverage is assessed by claim construction against:
  • Release mechanism limitations
  • Particle size or distribution constraints
  • Matrix or coating structures
  • Testing thresholds tied to pharmacokinetic profiles

When does Purdue’s patent exclusivity end, and how did it affect Watson’s launch timing in 1:12-cv-03111?

Featured-snippet answer: The litigation tracks the post-grant enforcement window, where expiration or settlement “design-around” timing determines whether a generic launch is barred or permitted.

Exclusivity vs. patent term

• Patent expiration governs whether a generic can legally market without infringement risk.
• Any settlement typically converts uncertainty into a scheduled launch event tied to:
  • Patent expiration dates
  • Carve-outs for non-infringing designs
  • Agreed limits on marketing until a later date

Practical impact on generic entry

• For Watson, the commercial risk is binary:
  • Enter “at risk” and face injunction/damages
  • Or delay/modify and enter after permitted date

Did Watson file a Paragraph IV challenge, and what is the litigation link to FDA ANDA practice?

Featured-snippet answer: Purdue’s enforcement against Watson’s competing product aligns with the ANDA framework where generic applicants challenge listed patents (often Paragraph IV) to seek approval and market entry.

Paragraph IV impact on litigation posture

• In Hatch-Waxman practice:
  • A Paragraph IV filing triggers a 30-month stay (unless earlier than the stay-triggering date via settlement or court timing).
  • Litigation decides whether the generic can launch while challenges are pending.

Why D.N.J. opioid formulation dockets often follow the same litigation mechanics

• These cases generally share:
  • Patent list disputes
  • Notice-based infringement assertions
  • Noninfringement and invalidity defenses
  • Speed and scheduling under statutory frameworks

How strong was Purdue’s patent case versus Watson’s invalidity and noninfringement arguments?

Featured-snippet answer: Purdue’s strength depended on claim constructions aligning extended-release mechanism limitations with Watson’s product evidence; Watson’s defenses typically targeted invalidity (anticipation/obviousness) and noninfringement.

Common invalidity theories in this product family

• Anticipation by prior art extended-release formulations
• Obviousness from combinations of prior teachings
• Defenses tied to specification enablement or written description (less common than anticipation/obviousness in these dockets, but present in some Purdue cases)

Common noninfringement theories

• Differences in formulation parameters
• Differences in release mechanism or performance characteristics
• Design-around changes that avoid specific claim limitations

What “strength” means operationally

• Courts that adopt Purdue-friendly constructions tend to narrow Watson’s path to “noninfringement without redesign.”
• If claim scope is broad, invalidity becomes the primary escape route.
• If claim scope is narrow, Watson’s main path is proving product differences.

What settlement terms typically apply in Purdue opioid formulation disputes like 1:12-cv-03111?

Featured-snippet answer: Settlements in this category typically include a release of claims, a structured entry date, and limits on product marketing tied to patent expiration or redesigned formulations.

Settlement components seen in enforcement dockets

• Payment or commercial consideration (in some dockets)
• Agreement on:
  • Launch timing
  • Modified product features
  • License terms (if any)
• Court docket closure via stipulation, dismissal, or consent judgment

How to map settlement to market impact

• Settlement dates determine:
  • When FDA approval can be leveraged for actual sales
  • When Purdue’s injunction risk drops for Watson
  • When other entrants can observe the permitted commercial pathway

What was the Orange Book status for the relevant Purdue product during 1:12-cv-03111?

Featured-snippet answer: Orange Book listings govern whether a generic applicant can file and what patents are actionable. In Purdue opioid litigation, the Orange Book governs listed patents tied to extended-release oxycodone products.

Orange Book mechanics that matter in these cases

• Patents listed by NDA holders are the targets for infringement suits.
• Litigation scope maps to those listed patents identified in the ANDA notice.

Why this matters for Watson’s risk profile

• If Purdue’s Orange Book listings were accurate and enforceable, Watson faced a narrower “freedom to operate.”
• If listings were contested or delayed, Watson’s litigation and settlement posture changed.

What generic entry risks existed for Watson after Purdue v. Watson 1:12-cv-03111?

Featured-snippet answer: Post-resolution, Watson’s risk depended on whether entry relied on:

• The same formulation that triggered infringement
• Or a redesigned product that avoided claim limitations

Key risk drivers

• Remaining unexpired patents not fully resolved in the docket
• Pending continuation patents or related formulation patents
• Additional asserted patents in subsequent litigation or parallel cases
• Regulatory labeling or indication constraints that could keep the product outside certain carve-outs

How does Purdue v. Watson 1:12-cv-03111 compare with other Purdue opioid formulation litigations?

Featured-snippet answer: The dispute fits the broader pattern of Purdue enforcing extended-release opioid formulation patents against generic entrants in Hatch-Waxman timelines.

Recurring litigation themes across Purdue opioid dockets

• Claim construction drives outcomes
• Product evidence (formulation composition and dissolution performance) is decisive
• Settlement often resolves the binary injunctive risk into a schedule

Where this docket may differ

• Differences typically arise from:
  • Exact asserted patent claims and claim language
  • Watson product design features
  • Timing of FDA approvals and any 30-month stay mechanics

Key procedural and commercial implications for stakeholders

For licensing and JV partners

• Purdue’s enforcement strategy in this docket suggests leverage tied to:
  • Claim scope control via construction
  • Tight linkage between formulation mechanics and patent claims
• Licensing or partnership routes would need:
  • Evidence showing noninfringement or design-around capability
  • Patent-specific freedom-to-operate analysis

For investors and litigation funding

• Settlement and entry dates control expected cash-flow timing.
• Patent estate strength in formulation-heavy opioid cases is sensitive to:
  • Claim construction outcomes
  • Validity findings and remaining unexpired patents

Timeline (high-level) for Purdue Pharma L.P. v. Watson Laboratories, Inc., 1:12-cv-03111

Date (year)	Event type	Litigation significance
2012	Case filed in D.N.J.	Initiation of Purdue’s enforcement against Watson’s competing product
2012-2013	Case management, infringement/invalidity briefing	Frames claim construction and evidence needs
2013	Claim construction (Markman)	Determines whether Watson’s product reads on Purdue claims
2013-2014	Dispositive motions and/or trial prep	Positions settlement or final judgment
Resolution (post-briefing)	Judgment and/or settlement-driven dismissal	Converts legal risk into market schedule

Key Takeaways

• Purdue v. Watson (1:12-cv-03111) is a standard Hatch-Waxman-era enforcement docket aimed at stopping or constraining extended-release opioid generic entry tied to Purdue’s formulation and controlled-release patent claims.
• The case’s commercial impact is driven by claim construction and by whether Watson’s product design avoided specific release-mechanism and formulation limitations.
• Resolution in this category typically leads to a scheduled entry pathway and clarifies Purdue’s leverage over future entrants using similar formulation attributes.

FAQs

1. What happens to market entry timelines when Purdue wins claim construction in opioid formulation litigation?
2. How do Orange Book patent listings determine what a generic can challenge in ANDA litigation?
3. What formulation changes most often avoid infringement in extended-release oxycodone patent estates?
4. How do ongoing or related Purdue continuations affect “freedom to operate” after a single docket resolves?
5. What evidence (dissolution testing, composition data, manufacturing records) is most decisive in Purdue-style extended-release patent disputes?

References

1. Purdue Pharma L.P. v. Watson Laboratories, Inc., No. 1:12-cv-03111 (D.N.J.) (court docket and filings).